Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. Click here to read more ...
Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...
As President Trump resumes his war, the focus is now on the Strait of Hormuz. But it remains unclear how far the U.S.
Delhi Metro has begun construction of the 12.37-km Inderlok-Indraprastha underground corridor, a Phase-IV project that will ...
India's economic fundamentals are stronger than they have been through much of the past two decades, but the country's next ...
The grid faltered during last weekend’s heat wave. Now BGE is asking regulators to approve a massive new transmission system ...
MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...
After monetising Big Sandy, Paul Lloyd is plan to turn Prairie Lithium’s Saskatchewan brine project from DLE promise into ...
Phase Two of the Shah Alam Light Rail Transit Line 3 (LRT3) project remains part of the government’s long term development plan and will include ...
(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...
Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results